ELN and inflammatory bowel disease: Of note, while anti-α4 therapies with humanized mAbs have been relatively successful for the treatment of multiple sclerosis (Tysabry) and IBD (Vedolizumab and AMG181), attempts to develop small-molecules selective α4β1 or α4β7 antagonists have failed until now, possibly for the same reasons for which ELN failed to protect against SHIV-SF162P3.